ANTIBODY DRUG CONJUGATION: FROM PRODUCT CONCEPT TO IND THROUGH INTEGRATED SOLUTIONS FROM DISCOVERY TO MANUFACTURE

Abzena understand that there is no one solution to the development of antibody drug conjugates and that every target brings its own set of challenges to the development process. Abzena can guide you in the development of a matrix of candidates that can be tested to find the ideal ADC for your target. Abzena utilise a range of conjugation technologies, which each have their own benefits, though no single option is optimal for every payload and antibody. Multiple conjugation technologies can be evaluated side-by-side to compare efficacy.

Please enter your details to access this article.